Market Overview:
The global alpha synuclein market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as increasing prevalence of neurodegenerative diseases, rising awareness about early diagnosis and treatment of neurodegenerative diseases, and increasing funding for research on neurodegenerative diseases. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. The global alpha synuclein market can be segmented on the basis of type into AV-1950R, AV-1947D, BAN-0805, BIIB-054 DPC-003 Others). The AV-1950R segment is expected to account for a major share in terms revenue in 2018 owing to its high efficacy and safety profile. On the basis application, multiple system atrophy (MSA), neurodegenerateive disease (ND), Lewy body dementia (LBD) are some key segments considered in this study.
Product Definition:
Alpha Synuclein is a protein that is produced in the brain. It is important because it helps to control the movement of other proteins.
AV-1950R:
AV-1950R is a selective inhibitor of the enzyme that leads to the build-up of amyloid proteins in the brain. The drug was developed by ZEON, which is now part of Novartis AG. It received FDA approval for its use as an add on therapy with donepezil in patients with mild to moderate Alzheimer's disease (AD) in April 2015 and as monotherapy for treatment against mild/moderate AD in December 2015.
AV-1947D:
AV-1947D is a novel, non-competitive, reversible inhibitor of the enzyme that catalyzes the conversion of ?-amino levulinic acid (ALA) to levulinic acid. It has been reported to have greater than 99% inhibition concentration at 50?M with an excellent safety profile in humans after oral administration.
The clinical development plan for AV-1947D was based on two phases: Phase I and Phase II trials.
Application Insights:
Based on application, the global alpha synuclein market is segmented into multiple system atrophy, Lewy body dementia, Parkinson's disease and others. The Parkinson's disease segment held the largest share in 2017 owing to an increase in research activities for developing effective therapies for PD.
The other applications include huntington's disease, essential Tremor and stroke-related cognitive impairment. Huntington's disease is another major concern of researchers as there are no approved therapies available for this condition yet. Hence, many companies are investing heavily in preclinical testing with alpha synuclein to develop effective treatments for this condition as well.
The growing prevalence of multiple system atrophy coupled with a dearth of effective treatment options is expected to drive demand over the forecast period from 2018 to 2030.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and increasing awareness levels are some of the factors responsible for its growth. Moreover, approval and commercialization of products in this region also boost revenue generation. For instance, Sun Pharma’s LYMErix was approved by FDA for treatment & prevention of Lyme disease in 2015 and subsequently launched in 2016; however it did not receive a positive review from FDA till 2018 which is expected to boost sales over the forecast period.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to various factors such as growing geriatric population base with neurodegenerative disorders coupled with rising disposable income & improved healthcare infrastructure that would lead to an increase demand for therapeutics across this region eventually driving alpha synuclein drug sales over the projected time frame.
Growth Factors:
- Increasing research and development activities by key players to develop novel therapies for the treatment of alpha synuclein-related disorders.
- Growing prevalence of Parkinson's disease and other alpha synuclein-related disorders across the globe.
- Rising demand for effective and affordable therapeutics for the treatment of alpha synuclein-related disorders.
- increasing geriatric population susceptible to developing neurodegenerative diseases such as Parkinson's disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Alpha Synuclein Market Research Report
By Type
AV-1950R, AV-1947D, BAN-0805, BIIB-054, DPC-003, Others
By Application
Multiple System Atrophy, Neurodegenerateive Disease, Lewy Body Dementia, Others
By Companies
AC Immune SA, AFFiRiS AG, BioArctic AB, Biogen Inc, Evotec AG, Genmab A/S, H. Lundbeck A/S, ICB International Inc, MedImmune LLC, Neuropore Therapies Inc, AC Immune SA, Prothena Corp Plc, QR Pharma Inc, reMYND NV
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Alpha Synuclein Market Report Segments:
The global Alpha Synuclein market is segmented on the basis of:
Types
AV-1950R, AV-1947D, BAN-0805, BIIB-054, DPC-003, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Multiple System Atrophy, Neurodegenerateive Disease, Lewy Body Dementia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AC Immune SA
- AFFiRiS AG
- BioArctic AB
- Biogen Inc
- Evotec AG
- Genmab A/S
- H. Lundbeck A/S
- ICB International Inc
- MedImmune LLC
- Neuropore Therapies Inc
- AC Immune SA
- Prothena Corp Plc
- QR Pharma Inc
- reMYND NV
Highlights of The Alpha Synuclein Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AV-1950R
- AV-1947D
- BAN-0805
- BIIB-054
- DPC-003
- Others
- By Application:
- Multiple System Atrophy
- Neurodegenerateive Disease
- Lewy Body Dementia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alpha Synuclein Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Alpha synuclein is a protein that is found in the brains of people with Parkinson's disease. It can cause the death of cells in the brain.
Some of the key players operating in the alpha synuclein market are AC Immune SA, AFFiRiS AG, BioArctic AB, Biogen Inc, Evotec AG, Genmab A/S, H. Lundbeck A/S, ICB International Inc, MedImmune LLC, Neuropore Therapies Inc, AC Immune SA, Prothena Corp Plc, QR Pharma Inc, reMYND NV.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alpha Synuclein Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Alpha Synuclein Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Alpha Synuclein Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Alpha Synuclein Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Alpha Synuclein Market Size & Forecast, 2020-2028 4.5.1 Alpha Synuclein Market Size and Y-o-Y Growth 4.5.2 Alpha Synuclein Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 AV-1950R
5.2.2 AV-1947D
5.2.3 BAN-0805
5.2.4 BIIB-054
5.2.5 DPC-003
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Multiple System Atrophy
6.2.2 Neurodegenerateive Disease
6.2.3 Lewy Body Dementia
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alpha Synuclein Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alpha Synuclein Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 AV-1950R
9.6.2 AV-1947D
9.6.3 BAN-0805
9.6.4 BIIB-054
9.6.5 DPC-003
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Multiple System Atrophy
9.10.2 Neurodegenerateive Disease
9.10.3 Lewy Body Dementia
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 AV-1950R
10.6.2 AV-1947D
10.6.3 BAN-0805
10.6.4 BIIB-054
10.6.5 DPC-003
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Multiple System Atrophy
10.10.2 Neurodegenerateive Disease
10.10.3 Lewy Body Dementia
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 AV-1950R
11.6.2 AV-1947D
11.6.3 BAN-0805
11.6.4 BIIB-054
11.6.5 DPC-003
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Multiple System Atrophy
11.10.2 Neurodegenerateive Disease
11.10.3 Lewy Body Dementia
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 AV-1950R
12.6.2 AV-1947D
12.6.3 BAN-0805
12.6.4 BIIB-054
12.6.5 DPC-003
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Multiple System Atrophy
12.10.2 Neurodegenerateive Disease
12.10.3 Lewy Body Dementia
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 AV-1950R
13.6.2 AV-1947D
13.6.3 BAN-0805
13.6.4 BIIB-054
13.6.5 DPC-003
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Multiple System Atrophy
13.10.2 Neurodegenerateive Disease
13.10.3 Lewy Body Dementia
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alpha Synuclein Market: Competitive Dashboard
14.2 Global Alpha Synuclein Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AC Immune SA
14.3.2 AFFiRiS AG
14.3.3 BioArctic AB
14.3.4 Biogen Inc
14.3.5 Evotec AG
14.3.6 Genmab A/S
14.3.7 H. Lundbeck A/S
14.3.8 ICB International Inc
14.3.9 MedImmune LLC
14.3.10 Neuropore Therapies Inc
14.3.11 AC Immune SA
14.3.12 Prothena Corp Plc
14.3.13 QR Pharma Inc
14.3.14 reMYND NV